CURRICULUM VITAE

**Date of revision: July 12, 2019**

**Name:** Andrea Lynn Maria Silber, M.D

## Title: Clinician in and Associate Clinical Professor of Medicine (Medical Oncology)

**School:** Yale University School of Medicine

**Education:**

B.A. Oberlin College, Ohio, 1977

M.D. New York University School of Medicine, New York, 1981

**Career/Academic Appointments:**

1981-1982 Intern, Internal Medicine, Yale University School of Medicine, New Haven, CT

1982-1985 Resident, Internal Medicine, Yale University School of Medicine, New Haven, CT

* 1. Chief Resident, Outpatient Medicine, Primary Care Center, Yale-New Haven Hospital, New Haven, CT
	2. Attending Physician, Emergency Room, Yale-New Haven Hospital, New Haven, CT
	3. Postdoctoral Fellow, Medical Oncology, Yale University School of Medicine,

New Haven, CT

1987-1995 Assistant Clinical Professor, Medicine, West Haven Veterans Hospital, Yale University

 School of Medicine, New Haven, CT

1996- 2011 Physician, Medical Oncology & Hematology, P.C., Father Michael J. McGivney Center for Cancer Care, Hospital of Saint Raphael, New Haven, CT

2008-Present Associate Clinical Professor, Yale University School of Medicine, Department of Internal Medicine, Section of Medical Oncology, New Haven, CT

2012-Present Clinician, Yale University School of Medicine, Department of Internal Medicine, Section

 of Medical Oncology, Smilow Cancer Hospital, St Raphael Care Center, New Haven, CT

**Administrative Positions:**

2015- Present Assistant Clinical Director for Diversity and Health Equity, Yale University School of Medicine, Yale Cancer Center, New Haven, CT

1994-2015 Director, Cancer Control and Early Detection Program, Father Michael J. McGivney Center for Cancer Care, Hospital of St Raphael, New Haven, CT

1994-2015 Director of Oncology, Yale Fellowship Program, Hospital of St Raphael,

 New Haven, CT

* 1. Chief of Evaluation, Veterans Administration Hospital, West Haven, CT

1987-1994 Director, Early Detection and Screening Clinic, Department of Medical Oncology

Yale University School of Medicine, New Haven, CT

**Board Certification & Licensure:**

American Board of Internal Medicine, Internal Medicine, 1984

American Board of Internal Medicine, Medical Oncology, 1991, recertified 2012

State of Connecticut Medical License, Current

**Professional Honors & Recognition:**

2019 Yale Cancer Center Award for Excellence in Clinical Care

2016 Connecticut Cancer Partnership 2016 Cancer Champion Award

2010 Women of Strength Award, Get In Touch Foundation

2009 Physician of the Year, Business New Haven

2007 Lane Adams Quality of Life Award

1998 Cover Girl Women at Their Best Award

1996-1997 Susan G. Komen National Award for “Sister-to-Sister”

1978-1981 National Health Service Corps Scholarship

1981 Fellowship in Philosophy and Medicine, NY School of Medicine

1977 Magna Cum Laude, Oberlin College

**Grant/Clinical Trials History:**

**Current Grants**

Agency: NIH/NCI

I.D.: R01 CA23044-01

Title: “Incarceration Related Cancer Outcomes (ICRO)"

PI: Cary Gross, M.D.

Role: Co-Investigator

Percent Effort: 2%

Total Cost: $794,567

Project Period: 08/01/2018-7/30/2022

Agency: NIH/NCI

I.D.: R01CA219647-01

Title: “Immune biological differences between Triple Negative Breast Cancer in African

American and non-African American women and potential immunotherapy opportunities to

improve treatment outcome”

PI: Lajos Pusztai, M.D., D.Phil

Role: Co- Investigator

Percent effort: 4%

Total cost: $1,178,627

Project Period: 09/01/2017 – 07/31/2021

Agency: NIH/NCI

I.D.: 2P30CA016359-39

Title: Yale Cancer Center Support Grant (CCSG) Community Outreach and Engagement

PI: Fuchs

Role: Co-Investigator

Percent Effort: 20%

Total Cost: $2,704,767

Project Period: 08/01/2018 – 07/31/2019

**Agency: Eli Lilly and Company**

**I.D.: CDC/Connecticut DPH**

**Title: Sponsorship**

**Role: Physician Champion**

**Percent Effort: 5%**

**Total Cost for Project Period: $180.000**

**Project Period: 09/01/2018 – 08/30/2021**

**Agency: Breast Cancer Alliance (BCA)**

**I.D.:**

**Title:** Comprehensive Breast Cancer Outreach and Support Program for Underserved Women:  Instilling Life-long Awareness about Breast Health, Providing Access to Screening, Early Treatment and Education about the Importance of Clinical Trials and Improving Outcomes

**Role: Physician Champion**

**Percent effort: 2%**

**Total cost: $25,000**

**Project Period: 02/15/2018 – 02/14/2019**

**Agency: NIH/NCI**

**I.D.: 1R01CA27753-01A1**

Title: A randomized trial of lifestyle guidelines on breast cancer biomarkers and treatment adherence

P.I.: Sanft

Role: Co-Investigator

Percent Effort: 2%

Total Cost: $414,997

Project Period: 04/01/2017-03/31/2022

Agency**:** Centers for Disease Control and Prevention (CDC)/Connecticut State Department of Public Health’s (DPH)

Comprehensive Cancer Screening Program (CCSP) – formerly known as the National Breast and Cervical Cancer Early Detection Program (NBCCEDP

**The program provides breast screening and diagnostic services for uninsured and underinsured in Connecticut**

Role: Physician Champion

Percent Effort: 2%

Direct Costs: $2,000,000

Project Period: 09/17/2012 – 09/16/2019

Eli Lilly and Company

Sponsorship

Role: Physician Champion

**Percent Effort: 2%**

Direct Costs: $180,000

Project Period: 09/01/2018 – 08/30/2021

**Current Clinical Trials:**

Current patients enrolled since January 2018 18

4/18 patients enrolled were African American

2/18 patients enrolled were Hispanic or Latino

Agency: Bristol-Myers Squibb Foundation (Herbst,Jones)

Yale Cancer Center

Title: Cancer Disparities Firewall

Role: Advisor

Percent Effort: 0%

Total Cost: $1,000,000

Project Period: 01/01/2018 – 12/31/2018

Agency: Southwest Oncology Group

I.D.: S1207; SC1212BRE012 (HIC01806)

Title: S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer (CIRB)

Role: Yale Site Principal Investigator

Total Costs for Project Period:

Project Period: 10/10/2013 - present

Agency: Eastern Cooperative Oncology Group

I.D.: 1607018160; EA1131

Title: EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs. Observation in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy (CIRB)

Role: Yale Site Principal Investigator

Total Costs for Project Period: N/A

Project Period: 04/10/2017 - Present

Agency: Calithera BioSciences

I.D.: CLEE011A2404/118397

Title: A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination with Paclitaxel in Patients with Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry

Role: Yale Site Principal Investigator

Total Costs for Project Period: N/A

Project Period: 12/21/2017 – 05/01/2020

Agency: Lilley/National Survival Adjuvant Breast and Bowel

I.D.: NSAPB-B-58

Title: B-58

FTE 0.100

Role: Yale Site Principal Investigator

Total Costs for Project Period: 90,258.00

Project Period: 02/20/2018 – present

Agency: Novartis

ID: 2000022291; BYLlieve

Title: A Phase II, multicenter, open-label, two-cohort, non-comparative study to assess the efficacy and safety of Alpelisib plus Fulvestrant or Letrozole in patients with PIK3CA mutant, hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after CDK 4/6 inhibitor treatment (HIC)

Role: Yale Site Principal Investigator

Total Costs for Project Period: N/A

Project Period: 11/30/2017 – Present

**Past Grants**

Comprehensive Breast Cancer Outreach and Support Program for Underserved Women: One Door to the Continuum of Care

Agency: Breast Cancer Alliance

Role: Physician Champion

Direct Costs: N/A

Total Costs for project year of funding: $25,000

Project Period: 01/01/16-12/31/16

Breast Cancer S.W.A.T. Team – We’ve got your back!

Agency: Connecticut Health and Educational Facilities Authority

Role: Principal Investigator/Medical Oncologist

Co-Investigator: Tish M. Knobf, Ph.D.

Percent Effort: 4 hours a week/0.100 FTE

Direct Costs: N/A

Total Costs for project year of funding: $75,000

Project Period: 07/01/15-07/01/16

Bridging the Care Continuum for Underserved Women with Metastatic Breast Cancer

Agency: The Avon Foundation for Women and Pfizer Oncology

Role: Principal Investigator/Medical Oncologist

Co-Investigator: Tish M. Knobf, Ph.D.

Percent Effort: 4 hours a week/0.100 FTE

Direct Costs: N/A

Total Costs for project year of funding: $35,000

Project Period: 04/01/15-03/31/16

Connecticut Breast and Cervical Cancer Early Detection Program

Wisewomen

Colorectal Cancer Screening

Agency: State of Connecticut/CDC Block Grant

Project Director- Andrea Silber, MD

Role: Site Director

Percent Effort: 10%

Direct Costs: N/A, contract executed through Hospital of Saint Raphael

Total costs for project period (2 years) – $279,179

Project funded from 1996-6/2013

Whitney-Griswold Fund, Yale University, New Haven, Connecticut, 1985

Connecticut Breast and Cervical Cancer Early Detection Program and Recipient, 1995, 1996, 1997

C.G. Swebilius Trust Award, 1995

Susan B. Komen Foundation Award, National Recipient, 1996

THIS CLOSE for Cancer Research, Inc. Award, 1996

Sisters of Charity Award, 1996

Hospital of Saint Raphael, Foundation Award, 2000

**Past Clinical Trials**

Agency: NSABP

Title: Study of Tamoxifen and Raloxifen -P2 Prevention Trial

Role: Principle Investigator – Hospital of Saint Raphael Site

Percent Effort- 10%

Funding: $1000 per patient

Project Period: 7/2000-7/2005

Award: Commendation, Andrea Silber, MD from NSABP for trial accrual, 2005

**PENDING**

**None**

**Research positions:**

2013 Research Collaborator, Yale Cancer Center, Pilot Program on MRI and Breast Cancer

2013Principal Investigator, Breast Cancer Awareness Month & Mammography, Yale University/ HIC approved study

**Invited Speaking Engagements, Presentations, Symposia & Workshops Not Affiliated With Yale**:

**Regional**

2018 Cancer Screening, Prevention, Treatment and Clinical Trials, Door of Salvation Church, New Haven, CT.

2018 Breast Cancer Awareness and Treatment, Mount Aery Baptist Church, Bridgeport, CT

2018 2nd NCI Cancer Health Disparities Research Symposium, “Biological Differences Between Triple Negative Breast Cancer in African American and Non-African American Women and Potential Immunotherapy Opportunities to Improve Treatment Outcome”, Washington DC

2017 Waterbury Hospital Grand Rounds, Waterbury, CT

2017 CareCard Sp17 Lecture, “Heart to Breast Health: A Special Session for Women, New Haven, CT

2017 Breast Cancer Alliance, Greenwich, CT

2017 Yale Alumni Association of Greenwich, CT

2017 Community Foundation of Greater New Haven Q & A

2017 Yale Affiliated Hospitals Program Medical Oncology Grand Rounds Speaker, Greenwich Hospital, Greenwich, CT

2016“Breast Cancer Screening, Treatment Prevention and Clinical Trials” Lecture in Spanish at Project Access-New Haven, Fair Haven, CT

2016 “Breast Cancer Screening, Treatment Prevention and Clinical Trials” Lecture at Project Access-New Haven, New Haven, CT

2016 “Breast Cancer Screening in Underserved Populations” Lecture at St. Mary’s Hospital

2015 Invited Speaker, 10th Annual UAB Health Disparities Research Symposium, Birmingham, AL: “Changing the Ratio: Racial and Ethnic Diversity in Cancer Clinical Trials in New Haven, CT”

2011 Keynote speech, Sister’s Journey, Pink Tea, *Breast Cancer Support Group*, Hamden, CT

2011 Lecturer, Public Health Lecture Series, Career High School, New Haven, CT

2007 Invited Speaker, New England Regional Minority Health Conference

**Peer-Reviewed Presentations & Symposia Given at Meetings Not Affiliated With Yale:**

**Regional**

2017 “An Evening Symposium on Breast Cancer”, Hartford, CT

2017 Total Health Conferencing, An Evening Symposium on Breast Cancer, New York, NY

2010 ASCO Breast Symposium, Washington D.C., ‘The Clinical & Public Health Implications of HSV Genital Infections during Adjuvant Chemotherapy for Breast Cancer’

**PROFESSIONAL SERVICE**

**Professional Organizations:**

2015-present Leadership Fellow, Connecticut Health Foundation

2008 – 2014 Board Member, American Cancer Society, New England Division

2008 – present Executive Board Member, Connecticut Cancer Partnership (State of CT)

2010 – present Co Chair, Health Care Disparities Resource Team, Connecticut Cancer Partner

**Memberships in Professional Societies:**

Fellow, American College of Physicians

Member, American Society of Clinical Oncology

Member, American Society of Preventative Oncology

**Yale University Service:**

***University Services***

2018 Member, Via Pathways Breast Medical Oncology Q1 Committee

2016 Member, Yale Cancer Center Director Search Committee

2015-present Co-Chair Health Equity and Diversity Committee

2015 Fellowship Interview Committee

2015 Member, Yale Cancer Center

1991 Consultant, Project on Aging, Yale University School of Epidemiology and Public Health

***Medical School Committees***

2015 Committee Member, Executive Committee of the Yale Cancer Center

2015 Member, Yale Cancer Center Grand Rounds Committee

2012-2013Board Member, Committee for Diversity and Health Equity, Yale Comprehensive Cancer Center

2012 – 2013 Planning Committee, Health Equity in Cancer Care, Yale University School of Medicine

1996 Member, Yale Comprehensive Cancer Center, School of Medicine

 PreMed Advisory Committee, Yale University

2012-present Physician Council, Smilow Cancer Hospital Care Center, Yale Cancer Center

**Hospital Boards & Committees:**

2015 Member, Breast Center Steering Committee, Smilow Cancer Hospital

2015 Clinical Research Working Group

2009 – 2014 Co Director, Women’s Center for Breast Health, Yale University, Saint Raphael

 Campus, New Haven, CT

1986 Consultant, Homeless Veterans Project, West Haven Veterans Hospital, CT

**Public Services:**

2019 National Association of Negro Business and Professional Women, New Haven, CT

2018 OwnIT Presentation, African American Women’s Union Summit, Beecher School, New Haven.

2018Sisters Journey, Triple Negative Breast Cancer Discussion, Beecher School, New Haven, CT

2017 New Haven Community Center Steering Committee, Yale Cancer Center Initiatives to improve cancer outcomes for minorities, Birchwood’s, Woodbridge, CT

2017 Local Women Leading Change: “Those Closest to the Challenge are Closest the Solution”, the Community Foundation, New Haven, CT

2017 Health Initiative Day, Breast Cancer Panel Discussion, New Haven, CT

 2017 Sisters Journey, St Luke’s Church, “New Advancements in treatment for Triple Negative Women”, New Haven, CT

2017 Latin Lean Cancer Survivors, contribution to a Healthy Diet, New Haven, CT

2012 Collaborator and Mentor, Cancer Awareness at New Haven Academy

2012 Consultant, Advisory Board, Novartis Pharmaceuticals

1992 Veterans Administration Task Force on Breast Screening

1986-1987 Consultant, Breast Cancer Screening for Medicare Beneficiaries, Office of Technology Assessment

**Journal Service:**

2005 – present Editorial Board Member, Connecticut Medicine

2005 – present Reviewer, Connecticut Medicine -Oncology

**Bibliography:**

**Peer-Reviewed Original Research**

1. Nardino R.J, **Silber AL**. “A Medical Home for a breast cancer Survivor.” *Connecticut Medicin*e, 2012 June-July;78(6) 365-7.
2. Salner AL, **Silber AL**. “Comprehensive cancer Control- impacting every physician.” *Connecticut Medicine*. 2012 June-July 78(6) 325-6.
3. **Silber ALM** and Horwitz RI. “Detection bias and the benign breast disease/breast cancer relationship.” *Lancet*, 1986, 638-640.
4. US Congress Office of Technology Assessment Health Program, Breast Cancer Screening for Medicare Beneficiaries: Effectiveness, Costs to Medicare and Medical Resources Required. November, 1987.
5. Wong B, Bernard E, Gold J, Fong D, **Silber A** and Armostrong D. “Increased arabinatol levels of experimental candidiasis in rats: Arabinatol appearance rates, arabinatol/creatinine ratios, and severity of infection.”  *Journal of Infectious Disease*, 1982 Sep;146(3):346-52.
6. **Silber ALM**. “Sister-to-Sister: A Program to Increase Breast Cancer Screening in African-American Women” (1997). 20th Annual San Antonio Breast Cancer Symposium.
7. **Silber, A.L.M**. (1999). New Horizons in the fight against Breast Cancer. *Connecticut Medicine*, 63, 3-4.
8. Haffty BG, Alvarez-Franco M, **Silber A,** Matloff E, and Bale A.E. BRCA1 and BRCA@ mutations in breast cancer patients of African American descent. *Breast Cancer Research Reports and Treatments.* 2000 :61.
9. Haffty B, **Silber A**, Matloff E, Chung J, Lannin D. “Racial Differences in the incidence of BRCA1 and BRCA2 mutations in a cohort of Early Onset Breast Cancer patients: African American compared to White Women.” *Journal of Medical Genetics*. June, 2005.
10. Haffty BG, Choi DH, Goyal S, **Silber A**, Ranieri K, Matloff E, Lee MH, Nissenblatt M, Toppmeyer D, Moran MS. “[Breast cancer in young women (YBC): prevalence of BRCA1/2 mutations and risk of secondary malignancies across diverse racial groups.](http://www.ncbi.nlm.nih.gov/pubmed/19491284)” *Ann Oncol*. 2009 Oct;20 (10):1653-9.
11. Nardino RJ, **Silber AL**. “A medical home for a breast cancer survivor.” *Conn Med*. 2012 Jun-Jul;76 (6):365-7.
12. Salner AL, **Silber AL**. “Comprehensive cancer control--impacting every physician.” *Conn Med*. 2012 Jun-Jul;76 (6):325-6.
13. Sanft T, Aktas B, Schroeder B, Bossuyt V, DiGiovanna M, Abu-Khalaf M, Chung G, **Silber A**, Hofstatter E, Mougalian S, Epstein L, Hatzis C, Schnabel C, Pusztai L. “Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer.” *Breast Cancer Res Treat.* 2015 Dec;154(3):533-41. PMCID: PMC4661200
14. Wang SY, Long JB, Killelea BK, Evans SB, Roberts KB, **Silber A**, Gross CP. “Preoperative Breast Magnetic Resonance Imaging and Contralateral Breast Cancer Occurrence Among Older Women With Breast Cancer. *J Clin Oncol*. 2016 Feb 1;34(4):321-8. PMCID: PMC4872032
15. Patel JM, Knopf J, Reiner E, Bossuyt V, Epstein L, DiGiovanna M, Chung G, **Silber A**, Sanft T, Hofstatter E, Mougalian S, Abu-Khalaf M, Platt J, Shi W, Gershkovich P, Hatzis C, Pusztai L. “Mutation based treatment recommendations from next generation sequencing data: a comparison of web tools.” *Oncotarget.* 2016 Apr 19;7(16):22064-76. PMCID: PMC5008344
16. Wang SY, Long JB, Killelea BK, Evans SB, Roberts KB, **Silber A**, Gross CP. “Preoperative breast magnetic resonance imaging and contralateral breast cancer occurrence among older women with ductal carcinoma in situ.” *Antimicrob Agents Chemother.* 2016 Jul;158(1):139-48
17. Shields PG, Herbst RS, Arenberg D, Benowitz NL, Bierut L, Luckart JB, Cinciripini P, Collins B, David S, Davis J, Hitsman B, Hyland A, Lang M, Leischow S, Park ER, Purcell WT, Selzle J, **Silber A**, Spencer S, Tanvetyanon T, Tiep B, Tindle HA, Tucker-Seeley R, Urbanic J, Hooper MW, Weksler B, Whitlock CW, Wood DE, Burns J, Scavone J. “Smoking Cessation, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.” *J Natl Compr Canc Netw.* 2016 Nov;14(11).
18. Dzimitrowicz H., Mougalian S., Storms S., Hurd S., Chagpar A., Killelea B., Horowitz N., Lannin D., Harigopal M., Hofstatter E., DiGiovanna M., Adelson Kl., **Silber A**., Abu-Khalaf M., Chung G., Zaheer W., Abdelghany O, Hatzis C., Pusztai L., and Sant T.. I[mpacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision Making.](https://www.ncbi.nlm.nih.gov/pubmed/29048991) 2017 *Journal Oncology Practice*. Dec;13(12):e1012-e1020.
19. Szekely B, Safonov AM, Karn T, Bhagwagar S, Killelea BK, **Silber A**, Hatzis C, Pusztai L. Differences in the immune microenvironment and genomic characteristics of TNBC in African American women compared to other races. *J Clin Oncol* 2017, 35:(15\_suppl, abstract e13028).
20. Chagpar A., Horowitz N., Sanft T., Wilson L., **Silber A**., Killelea B., Moran M. DiGiovanna M., Hofstatter E., Chung G., Pusztai L., and Lannin D.. Discussion of: "Does lymph node status influence adjuvant therapy decision-making in women 70 years of age or older with clinically node negative hormone receptor positive breast cancer?" 2017 *American Journal of Surgery*. Dec; 214(6):1089-1090.
21. Mougalian SS., Epstein L., Jhaveri A., Han G., Abu-Khalaf M., Hofstatter E., DiGiovanna M., **Silber A**., Adelson K., Pusztai L., Gross C.. Bi-Directional Text Messaging to Monitor Endocrine Therapy Adherence and Patient-Reported Outcomes in Breast Cancer. 2017 *Journal of Clinical Oncology*. Nov 1.1-10. PMID 30657377
22. Chagpar A., Horowitz N., Sanft T., Wilson L., **Silber A**., Killelea B., Moran M., DiGiovanna M., Hofstatter E., Chung G., Pusztai L., and Lannin D.. Does lymph node status influence adjuvant therapy decision-making in women 70 years of age or older with clinically node negative hormone receptor positive breast cancer? 2017 *American Journal of Surgery*. Dec;214(6):1082-1088.
23. Szekely B, **Silber A**, Pusztai L. “New Therapeutic Strategies for Triple-Negative Breast Cancer.” *Oncology Journal( Williston Park)*, 2017 Feb 15;31(2):130-7.
24. Wang S., Long J., Killelea B., Evans S., Roberts K., **Silber A**., Davidoff A., Sedghi T., Gross C.. Associations of preoperative breast magnetic resonance imaging with subsequent mastectomy and breast cancer mortality. 2018 Breast *Cancer Res Treat* Nov;172(2):453-461. PMCID6193824
25. Szekely B, Bossuyt V, Li X, Baine M, **Silber A**, Sanft T, Hofstatter E, Mougalian S, Bhagwagar

 S, Neumeister V, Pelekanou V, Hatzis C, Pusztai L. Immunological differences between primary

 and metastatic breast cancer. *Cancer Res* 2018, PD6-02-PD6-02.

1. Foldi J, Mougalian S., **Silber A**., Lannin D., Killelea B., Chagpar A., Horowitz N., Frederick C., Rispoli L., Burrello T., Abu-Khalaf M., Sabbath K., Sanft T., Brandt DS., Hofstatter E., Hatzis C., DiGiovanna M., and Pusztai L.. Single-Arm, neoadjuvant, phase II trial of pertuzamab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I-III HER2-positive breast cancer. 2018 *Breast Cancer Research and Treatment*, Jun; 169(2):333-340.
2. Trant AA, Szekely B, Mougalian SS, DiGiovanna MP, Sanft T, Hofstatter E, **Silber A**, Adelson KB, Chagpar A, Killelea B, Horowitz N, Lannin D, Park T, Corso M, Abraham G, Pollard-Murphy K, Sturrock T, Knill-Selby E, Western A, Servodidio C, Tasoulis MK, Healy B, Hatzis C, Pusztai L., The Impact of Communication Style on Patient Satisfaction. Breast Cancer Research Treatment 2019, April 25 (epub ahead of print)

Scholarship in Press

1. Foldi J., O’Meara T., Marczyk M., **Silber, A**., Sanft, T. and Pusztai, L.. “Defining risk of late recurrence in early stage estrogen receptor-positive breast cancer; clinical versus molecular tools”. 2019 *Journal of Clinical Oncology*
2. O’Meara T., Safonov A., Casadevall D., Qing T., **Silber A**., Kilelea B., Hatzis C., and Pusztai L.. Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women. 2019 *Breast Cancer Research and Treatment*, 10.1007/s10549-019-05156-5.